What is familial partial lipodystrophy type 5 (FPLD5)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Familial type 5 lipodystrophy is a rare genetic disorder characterized by abnormal fat distribution in the body, specifically involving the loss of subcutaneous fat from the extremities and accumulation of fat in the trunk, face, and neck. This condition is also known as Dunnigan-type familial partial lipodystrophy (FPLD2) and typically becomes apparent during puberty, especially in women 1. The disorder is caused by mutations in the LMNA gene, which provides instructions for making proteins called lamins A and C that play important roles in cell structure and function. Some key features of familial type 5 lipodystrophy include:

  • Progressive loss of subcutaneous fat from the limbs, buttocks, and trunk
  • Abnormal accumulation of fat in the face, neck, and intra-abdominal regions
  • Metabolic complications such as insulin resistance, diabetes mellitus, high triglycerides, and low HDL cholesterol
  • Increased risk of fatty liver disease and polycystic ovary syndrome in women
  • Potential fertility issues in women The management of familial type 5 lipodystrophy focuses on treating the metabolic complications through:
  • Diet and exercise
  • Medications such as metformin for diabetes
  • Statins or fibrates for dyslipidemia
  • Leptin replacement therapy in some cases Early diagnosis and treatment are crucial to prevent long-term complications like cardiovascular disease, as seen in other lipodystrophic disorders 1.

From the Research

Definition and Classification of Lipodystrophy

  • Lipodystrophy syndromes are rare heterogeneous disorders characterized by deficiency of adipose tissue, usually a decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia 2.
  • Lipodystrophy is classified as genetic or acquired and by the distribution of fat loss, which can be generalized or partial 2, 3.

Types of Lipodystrophy

  • The two most common types of genetic lipodystrophies are autosomal recessive congenital generalized lipodystrophy and autosomal dominant familial partial lipodystrophy (FPL) 4.
  • Familial partial lipodystrophy (FPL) is a type of lipodystrophy that is characterized by selective loss of body fat and predisposition to insulin resistance 4.

Familial Type 5 Lipodystrophy

  • There is no specific information available on familial type 5 lipodystrophy in the provided studies.
  • However, it can be inferred that familial type 5 lipodystrophy may be a subtype of familial partial lipodystrophy, which is characterized by selective loss of body fat and predisposition to insulin resistance 4.

Management and Treatment

  • Effective management of lipodystrophy includes lifestyle changes and aggressive, evidence-based treatment of comorbidities 2.
  • Leptin replacement therapy (metreleptin) has been found to improve metabolic parameters in many patients with lipodystrophy 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnosis and treatment of lipodystrophy: a step-by-step approach.

Journal of endocrinological investigation, 2019

Research

Lipodystrophies-Disorders of the Fatty Tissue.

International journal of molecular sciences, 2020

Research

Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.

The Journal of clinical endocrinology and metabolism, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.